Thursday 16 October, 2025
Objectives: Meletios Therapeutics is currently developing MLT103 (compound initially evaluated in the 1990s) with various pharmacological properties: it is a…
Read morePoster: Methodology - Covariate/Variability Models
Estimating a Cox proportional hazard model in NONMEM
Thursday 16 October, 2025
Objectives: Traditionally the most commonly used model for survival analysis is the Cox proportional hazard (Cox PH) model [1]. The…
Read moreThe Population Pharmacokinetics of Active Metabolites of a prodrug PF-0417132, (Dissociated Agonist of Glucocorticoid Receptor), in Rheumatoid Arthritis subjects
Thursday 16 October, 2025
Objectives: Develop a PK model for PF-00251802 (parent) and its active metabolite PF-04015475 after oral administration of the prodrug PF-0417132….
Read moreEfficient and relevant stepwise covariate model building for pharmacometrics
Thursday 16 October, 2025
Background: Covariate modeling is an important opportunity for pharmacometrics to influence decision-making in drug development. The stepwise covariate model (SCM)[1] building…
Read moreIncreasing the efficiency of the covariate search algorithm in the SCM
Thursday 16 October, 2025
Objectives: To compare the efficiency of the legacy SCM covariate search algorithm [1] to the new SCM+ algorithm. Methods: The SCM+…
Read morePopulation PK analysis of Sym004 and the influence of variations in base model structure on covariate model building
Thursday 16 October, 2025
Objectives: Sym004 is a mixture of two synergistic full-length anti-EGFR antibodies (futuximab & modotuximab) that bind to 2 separate non-overlapping epitopes…
Read morePopulation PK analysis with full and reduced covariate models for Sym004, an antibody mixture targeting EGFR
Thursday 16 October, 2025
Introduction: Sym004 is a mixture of two synergistic full-length anti-EGFR antibodies (futuximab & modotuximab) that bind to two separate non-overlapping…
Read moreHorseshoe prior as a fast and efficient approach for covariate selection in pharmacometric modelling
Thursday 16 October, 2025
Introduction: Covariate model building is a crucial step in pharmacometric analyses. The selected covariate model may be used to support…
Read moreImpact of Size-Related Covariates on the Central Volume and Clearance of Monoclonal Antibodies
Thursday 16 October, 2025
Objectives The dosing of monoclonal antibodies (mAbs) in oncology is often based on body size, despite evidence suggesting that fixed…
Read moreUsing Full Random Effects Models (FREM) in different software
Thursday 16 October, 2025
Introduction: The Full Random Effect Modelling (FREM)[1] is an innovative approach for exploring covariate effects in mixed effect models. Unlike…
Read more